Business Context and Reporting Period
This Form 8-K was filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on September 8, 2021. The report addresses a corporate action regarding the company's 6% Convertible Exchangeable Preferred Stock (CYCCP). The registrant is incorporated in Delaware and maintains its principal executive offices in Berkeley Heights, NJ.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to a dividend declaration:
- Dividend Amount: $0.15 per share on 6% Convertible Exchangeable Preferred Stock.
- Record Date: October 15, 2021.
- Payment Date: November 1, 2021.
Material Changes
The material event reported is the Board of Directors' declaration of a quarterly cash dividend. The Board noted that this decision followed a requisite financial analysis and a determination of surplus. No other material changes to operations or financial position are detailed in this specific filing.
Guidance, Outlook, and Risks
Management provided limited forward-looking commentary regarding future dividends. While the Board will analyze the advisability of declaring dividends in future quarters, the filing explicitly states there is no assurance that future quarterly dividends will be declared.
Investor Verification Checklist
- Verify the number of shares of 6% Convertible Exchangeable Preferred Stock held to calculate total dividend entitlement.
- Confirm the record date (October 15, 2021) to ensure eligibility for the November 1, 2021 payment.
- Review the company's most recent 10-Q or 10-K to assess the "surplus" determination mentioned by the Board, as this filing does not contain full financial statements.
- Monitor future filings for confirmation of subsequent dividend declarations, as none are guaranteed.